Prodrug strategies for improved efficacy of nucleoside antiviral inhibitors

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Current Opinion in HIV and AIDS

• Publication date

  2013-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1097/COH.0000000000000007PMID 24100876PMCID PMC7722247
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients.

  2014cited by this paper
• Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA

  2013cited by this paper
• Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

  2013cited by this paper
• Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.

  2013cited by this paper
• Sofosbuvir for previously untreated chronic hepatitis C infection.

  2013cited by this paper
• Comparative Effectiveness of Antiviral Treatment for Hepatitis C Virus Infection in Adults: A Systematic Review

  2013cited by this paper
• Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents.

  2013cited by this paper
• tenofovir ‐ based regimens during treatment failure of subtype C HIV ‐ 1 in South Africa

  2013cited by this paper
• Resistance to Tenofovir-Based Regimens during Treatment Failure of Subtype C HIV-1 in South Africa

  2013cited by this paper
• Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

  2013cited by this paper
• Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance

  2013cited by this paper
• First Pharmacokinetic and Safety Study in Humans of the Novel Lipid Antiviral Conjugate CMX001, a Broad-Spectrum Oral Drug Active against Double-Stranded DNA Viruses

  2012cited by this paper
• Resistance to Mericitabine, a Nucleoside Analogue Inhibitor of HCV Rna-Dependent RNA Polymerase

  2012cited by this paper
• Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients.

  2012cited by this paper
• Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology

  2012cited by this paper
• Comparative assessment of In Vitro-In Vivo extrapolation methods used for predicting hepatic metabolic clearance of drugs.

  2012cited by this paper
• Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches

  2012cited by this paper
• Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.

  2012cited by this paper
• Antivirals for Management of Herpes Zoster Including Ophthalmicus: A Systematic Review of High-Quality Randomized Controlled Trials

  2012cited by this paper
• Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B.

  2011cited by this paper
• Application of kinase bypass strategies to nucleoside antivirals.

  2011cited by this paper
• Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.

  2010cited by this paper
• Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies.

  2010cited by this paper
• Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977

  2010influential reference
• The role of intestinal carboxylesterase in the oral absorption of prodrugs.

  2010cited by this paper
• Mechanistic basis of using body size and maturation to predict clearance in humans.

  2009cited by this paper
• Lack of Pharmacokinetic Interaction between Amdoxovir and Reduced- and Standard-Dose Zidovudine in HIV-1-Infected Individuals

  2009cited by this paper
• Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.

  2009cited by this paper
• Modeling complex decay profiles of hepatitis B virus during antiviral therapy

  2009cited by this paper
• Database for Physiologically Based Pharmacokinetic (PBPK) Modeling: Physiological Data for Healthy and Health-Impaired Elderly

  2009cited by this paper
• Strategies to increase the oral bioavailability of nucleoside analogs.

  2009cited by this paper
• Development of an Optimized Dose for Coformulation of Zidovudine with Drugs That Select for the K65R Mutation Using a Population Pharmacokinetic and Enzyme Kinetic Simulation Model

  2008cited by this paper
• Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and Other Tenofovir Phosphonoamidate Prodrugs by Human Proteases

  2008cited by this paper
• The mechanism of action of beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine involves a second metabolic pathway leading to beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.

  2008cited by this paper
• Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]- Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections

  2007cited by this paper
• The Mechanism of Action of β-d-2′-Deoxy-2′-Fluoro-2′-C-Methylcytidine Involves a Second Metabolic Pathway Leading to β-d-2′-Deoxy-2′-Fluoro-2′-C-Methyluridine 5′-Triphosphate, a Potent Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

  2007cited by this paper
• Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.

  2007cited by this paper
• Development of a Population Simulation Model for HIV Monotherapy Virological Outcomes Using Lamivudine

  2007cited by this paper
• Characterization of the Metabolic Activation of Hepatitis C Virus Nucleoside Inhibitor β-d-2′-Deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and Identification of a Novel Active 5′-Triphosphate Species*

  2007cited by this paper
• Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]-Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections

  2007cited by this paper
• Synergistic Efficacy of the Combination of ST-246 with CMX001 against Orthopoxviruses

  2007cited by this paper
• Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication.

  2006cited by this paper
• Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses.

  2006cited by this paper
• Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy

  2006cited by this paper
• Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue

  2005cited by this paper
• Antiviral drug discovery and development: where chemistry meets with biomedicine.

  2005cited by this paper
• Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay.

  2004cited by this paper
• The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins

  2004cited by this paper
• Antiretroviral Efficacy and Pharmacokinetics of Oral Bis(isopropyloxycarbonyloxymethyl)9-(2-Phosphonylmethoxypropyl)adenine in Mice

  1998cited by this paper
• Pharmacokinetics and Bioavailability of the Anti-Human Immunodeficiency Virus Nucleotide Analog 9-[(R)2-(Phosphonomethoxy)Propyl]Adenine (PMPA) in Dogs

  1998cited by this paper
• Metabolism and Pharmacokinetics of Novel Oral Prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in Dogs

  1997cited by this paper
• In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver.

  1997cited by this paper
• Famciclovir, from the bench to the patient--a comprehensive review of preclinical data.

  1996cited by this paper
• The Clinical Pharmacokinetics of Famciclovir

  1996cited by this paper
• Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver.

  1995cited by this paper
• Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults

  1995cited by this paper
• Famciclovir for the Treatment of Acute Herpes Zoster: Effects on Acute Disease and Postherpetic Neuralgia: A Randomized, Double-Blind, Placebo-Controlled Trial

  1995cited by this paper
• Use of isotopically chiral [4'-13C]famciclovir and 13C NMR to identify the chiral monoacetylated intermediates in the conversion of famciclovir to penciclovir by human intestinal wall extract.

  1993cited by this paper
• Broad-spectrum antiviral activity of carbodine, the carbocyclic analogue of cytidine

  1990cited by this paper
• Biochemical Pharmacology of Acyclic Nucleotide Analogues

  1990cited by this paper

• Prodrug strategies in developing antiviral nucleoside analogs

  2026cites this paper
• Identification of 4'-Thiouridine as an Orally Available Antiviral Agent Targeting Both RdRp and NiRAN Functions of SARS-CoV-2 Nsp12.

  2025cites this paper
• Transmembrane Transport of cAMP and AMP Using a Two Component Small Molecule Transport System

  2025cites this paper
• Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections

  2024cites this paper
• Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of SA001 and Its Active Metabolite Rebamipide after Single and Multiple Oral Administration

  2023cites this paper
• Discovery of an L‐like Configuration for 3’‐Fluoro‐5’‐norcarbonucleoside Phosphonates as Potent Anti‐HIV Agents

  2022cites this paper
• A comprehensive review of in silico approaches for the prediction and modulation of aldehyde oxidase-mediated drug metabolism: The current features, challenges and future perspectives.

  2021cites this paper
• Phase Ib Trial To Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of Filociclovir (MBX-400, Cyclopropavir) in Healthy Volunteers

  2019cites this paper
• Sofosbuvir inhibits hepatitis A virus replication in vitro assessed by a cell‐based fluorescent reporter system

  2018cites this paper
• Cell-line dependent antiviral activity of sofosbuvir against Zika virus.

  2017cites this paper
• Substrates and Inhibitors of SAMHD1

  2017cites this paper
• Strategies in the designing of prodrugs, taking into account the antiviral and anticancer compounds.

  2017cites this paper
• Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

  2016cites this paper
• Design, synthesis and antiviral evaluation of 2'-C-methyl branched guanosine pronucleotides: the discovery of IDX184, a potent liver-targeted HCV polymerase inhibitor.

  2015cites this paper
• Nucleoside Phosphate-Conjugates Come of Age: Catalytic Transformation, Polymerase Recognition and Antiviral Properties.

  2015cites this paper
• Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo Acids

  2015cites this paper
• Analysis of Tautomeric Equilibrium of the Analogue d(dinitro-tC(O))TP During Incorporation by the Klenow Fragment of DNA Polymerase I

  2014cites this paper
• Synthesis of Nucleoside Phosphate and Phosphonate Prodrugs

  2014cites this paper